Provectus Pharmaceuticals, Inc. announced that a patent application has been published for US and international patents covering the combination of local and systemic immunomodulative therapies for cancer treatment. The patent, entitled "Combination of Local and Systemic Immunomodulative Therapies for Enhanced Treatment of Cancer," covers a cancer treatment method that comprises administering a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. The systemic immunomodulatory anticancer agent comprises anti-CTLA-4 antibodies including ipilimumab and tremelimumab. Additionally, Provectus Pharmaceuticals presented final top-line data from its Phase 2 clinical trial of PV-10 for metastatic melanoma at the European Society for Medical Oncology 2012 Congress in Vienna, Austria October 1, 2012. The data were presented in Abstract #1137P, "Immuno-chemoablation of metastatic melanoma with intralesional rose bengal" by Sanjiv Agarwala, MD, principal investigator. Of the results, analysis of temporal data showed that Stage III subjects experienced significantly greater mean progression-free survival of at least 9.7 months, versus 3.1 months for Stage IV subjects. The poster is available at http://www.pvct.com/publications/PVCT-ESMO-2012-Poster.pdf.